---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004325"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:20:02.530556+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# KALA BIO reports FY23 net loss $42.2M; Phase 2b PCED trial data expected YE 2024

## Summary
- Q4 2023 net loss $8.6M ($3.18/sh) vs $12.8M ($7.97/sh) in Q4 2022.
- FY 2023 net loss $42.2M ($17.35/sh) vs $44.8M ($29.48/sh) in FY 2022.
- Cash $50.9M at Dec 31, 2023; with $8.6M Mar 2024 placement, runway into Q3 2025.
- R&D expenses Q4 $4.7M (up from $3.3M) driven by KPI-012 development costs.
- KPI-012 Phase 2b CHASE trial for PCED enrolling; topline data targeted by year-end 2024.

## SEC filing metadata
- accession: 0001558370-24-004325
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/0001558370-24-004325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/kala-20240329x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004325
- JSON: https://secwatch.observer/filing/0001558370-24-004325.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004325.txt

## Key facts
- Earnings Releases
  KALA BIO, Inc. reported financial results for the quarter and year ended December 31, 2023.
  - Period: the quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 29, 2024, KALA BIO, Inc. announced its financial results for the quarter and year ended December 31, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837024004325/0001558370-24-004325-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.